The drug Zolgensma has been added effective 09/01/2019 to the list of Reinsured Biological Drugs (BIO case type). Zolgensma is a gene therapy indicated for treatment of pediatric patients less than 2 years of age with spinal muscular atrophy. The process for Reinsurance for the drug will be the same as for other Biological Drugs but due to the high dollar nature of Zolgensma, contractor reinsurance analysts will need to monitor these cases closely so High Dollar Catastrophic Coverage (CRB Case) can be requested once CRNs associate to the BIO case. AHCCCS Reinsurance will be able to transfer partial dollar values of CRNs to ensure the BIO cases remain at $1,000,000.00 per Reinsurance policy and that the CRB case will receive the maximum reimbursement possible. For example, if there are two Zolgensma Form C claims on a BIO case for $999,999.99 each, reinsurance will be able to transfer $999,999.98 to the CRB case while allowing $1,000,000.00 to remain on the BIO case.

Note: CY37 BIO cases have a $0.00 deductible and pay at 85% of Reinsurance Case Total.
CY37 CRB cases have a $0.00 deductible and pay at 100% of Reinsurance Case Total

Have a great day!
Reinsurance Staff

If any additional information is needed, contact
Tracy.Thomas@azahcccs.gov